US 9877952
Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
granted A61KA61K31/4245A61K47/02
Quick answer
US patent 9877952 (Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy) held by PTC THERAPEUTICS, INC. expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K31/4245, A61K47/02, A61K47/10, A61K47/12